EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The tissue factor-TFPI pathway as a therapeutic target in bleeding disorders of unknown cause

Elena Monzón Manzano, Paula Acuña, Mónica Martín Salces, María Isabel Rivas Pollmar, Eduardo García Pérez, José Manuel Martín de Bustamante González-Iglesias, Mar Gutiérrez, Víctor Jiménez Yuste, Nora Butta, María Teresa Álvarez Román

Journal of Thrombosis and Haemostasis · 2026-11 · 24 (11) · 3874-3883

DOI: 10.1016/j.jtha.2026.08.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-11. Verfasst von Elena Monzón Manzano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Haematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-IdiPAZ, Madrid, Spain. Hauptthemen laut MEDLINE: Thromboplastin, Lipoproteins, Hemorrhage. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk A/S, ISCIII.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bleeding disorders of unknown cause (BDUC) comprise a heterogeneous group of conditions characterized by clinically significant bleeding despite normal results on standard hemostatic investigations. OBJECTIVES: To investigate tissue factor (TF)-dependent coagulation in patients with BDUC and to evaluate the in vitro ability of concizumab and recombinant activated factor VII (rFVIIa) to restore thrombin generation. METHODS: Thrombin generation was assessed using an assay designed to isolate TF-dependent coagulation by inhibiting contact pathway activation with corn trypsin inhibitor. Tissue factor pathway inhibitor (TFPI) activity was measured. RESULTS: A subgroup of patients with BDUC exhibited impaired thrombin generation under these conditions. Reduced thrombin generation was frequently associated with increased TFPI activity, suggesting that excessive inhibition of TF-mediated coagulation contributes to the bleeding phenotype in a subset of patients. In vitro addition of concizumab or rFVIIa restored thrombin generation, indicating that defects in TF-dependent coagulation can be pharmacologically corrected. CONCLUSION: These findings identify dysregulation of the TF-TFPI axis as a potential pathophysiological mechanism underlying bleeding in a subset of patients with BDUC and highlight TFPI inhibition and rFVIIa administration as potential therapeutic approaches. However, the absence of abnormalities in all patients supports the concept that BDUC represents a biologically heterogeneous group of disorders with multiple underlying mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThromboplastinLipoproteinsHemorrhageHumansFactor VIIaRecombinant ProteinsAntibodies, Monoclonal, HumanizedThrombinBlood CoagulationFemaleMaleMiddle AgedSignal TransductionAdult

Stichwörter der Autor:innen

bleedingcoagulationthrombintissue factortissue factor pathway inhibitor

Substanzen

lipoprotein-associated coagulation inhibitorThromboplastinLipoproteinsFactor VIIaRecombinant ProteinsAntibodies, Monoclonal, HumanizedThrombinrecombinant FVIIaconcizumab

Autor:innen und Institutionen

  • Haematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-IdiPAZ, Madrid, Spain.
  • Haematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-IdiPAZ, Madrid, Spain; Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain.
  • Haematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-IdiPAZ, Madrid, Spain. Electronic address: nora.butta@salud.madrid.org.

Förderung

  • Novo Nordisk A/S
  • ISCIII

Zitieren

APA

Monzón Manzano, E., Acuña, P., Martín Salces, M., Rivas Pollmar, M. I., García Pérez, E., Martín de Bustamante González-Iglesias, J. M., Gutiérrez, M., Jiménez Yuste, V., Butta, N., & Álvarez Román, M. T. (2026). The tissue factor-TFPI pathway as a therapeutic target in bleeding disorders of unknown cause. Journal of Thrombosis and Haemostasis, 24(11), 3874-3883. https://doi.org/10.1016/j.jtha.2026.08.016

Vancouver

Monzón Manzano E, Acuña P, Martín Salces M, Rivas Pollmar MI, García Pérez E, Martín de Bustamante González-Iglesias JM, et al. The tissue factor-TFPI pathway as a therapeutic target in bleeding disorders of unknown cause. Journal of Thrombosis and Haemostasis. 2026;24(11):3874-3883. doi:10.1016/j.jtha.2026.08.016

BibTeX
@article{MonznManzano2026,
  author = {Monzón Manzano, Elena and Acuña, Paula and Martín Salces, Mónica and Rivas Pollmar, María Isabel and García Pérez, Eduardo and Martín de Bustamante González-Iglesias, José Manuel and Gutiérrez, Mar and Jiménez Yuste, Víctor and Butta, Nora and Álvarez Román, María Teresa},
  title = {The tissue factor-TFPI pathway as a therapeutic target in bleeding disorders of unknown cause},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {11},
  pages = {3874--3883},
  doi = {10.1016/j.jtha.2026.08.016}
}
Kostenlos starten →